874638-80-9 Usage
Description
((2R,3R,4R)-3-(benzoyloxy)-4-fluoro-4-methyl-5-oxotetrahydrofuran-2-yl)methyl benzoate is a complex organic compound with a unique molecular structure. It is characterized by its chiral centers at the 2nd, 3rd, and 4th carbon atoms, which are all in the R configuration. The molecule contains a benzoyloxy group, a fluorine atom, and a methyl group, as well as a tetrahydrofuran ring and a benzoate group. ((2R,3R,4R)-3-(benzoyloxy)-4-fluoro-4-methyl-5-oxotetrahydrofuran-2-yl)methyl benzoate has potential applications in various fields due to its specific chemical properties.
Uses
Used in Pharmaceutical Industry:
((2R,3R,4R)-3-(benzoyloxy)-4-fluoro-4-methyl-5-oxotetrahydrofuran-2-yl)methyl benzoate is used as a neuromuscular blocking agent for its ability to selectively bind to and inhibit the function of specific receptors in the neuromuscular junction, leading to muscle relaxation.
Used in Chemical Synthesis:
((2R,3R,4R)-3-(benzoyloxy)-4-fluoro-4-methyl-5-oxotetrahydrofuran-2-yl)methyl benzoate is used as a reactant in the synthesis of 1''-C-cyano-2''-fluoro-2''-C-methyl pyrimidine nucleosides, which are HCV polymerase inhibitors. These nucleosides have potential applications in the development of antiviral drugs for the treatment of Hepatitis C virus infections.
Check Digit Verification of cas no
The CAS Registry Mumber 874638-80-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,7,4,6,3 and 8 respectively; the second part has 2 digits, 8 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 874638-80:
(8*8)+(7*7)+(6*4)+(5*6)+(4*3)+(3*8)+(2*8)+(1*0)=219
219 % 10 = 9
So 874638-80-9 is a valid CAS Registry Number.
874638-80-9Relevant articles and documents
BI- AND MONOCYCLIC NUCLEOSIDE ANALOGS FOR TREATMENT OF HEPATITIS E
-
, (2021/10/22)
The present disclosure is directed toward bi- and monocyclic nucleoside analogs, and compositions comprising these compounds for use in the treatment of hepatitis E infections.
Preparation method of sofosbuvir key intermediate
-
, (2020/07/15)
The invention discloses a preparation method of a sofosbuvir key intermediate ((2R,3R,4R,5R)-3-(benzoyloxy)-5-chloro-4-fluoro-4-methyltetrahydrofuran-2-yl)benzoic acid methyl ester. The preparation method comprises the following steps: by using (R)-2,2-dimethyl-1,3-dioxolane-4-carboxylic acid as a starting material, performing acylating chlorination, performing a reaction with alpha-fluoropropionic acid, performing carbonyl reduction, performing hydroxyl protection, performing hydrolytic cyclization, performing hydroxymethyl protection, performing reduction, and performing chlorination to prepare the sofosbuvir key intermediate ((2R,3R,4R,5R)-3-(benzoyloxy)-5-chloro-4-fluoro-4-methyltetrahydrofuran-2-yl)benzoic acid methyl ester. The preparation scheme has a short synthetic route and a high yield, and avoids a fluorination reaction step in the synthetic process.
PROCESS FOR PREPARATION OF LACTONE DERIVATIVES AND INTERMEDIATES THEREOF
-
, (2018/03/09)
A novel process for the preparation of lactone derivatives, and intermediates thereof is described. The lactone derivatives are important precursors for the synthesis of anti-hepatitis C virus agents, including sofosbuvir.